SE461013B - Farmaceutisk komposition verksam mot lungobstruktioner bestaaende av en betaadrenerg antagonist och ett tyroideahormon - Google Patents

Farmaceutisk komposition verksam mot lungobstruktioner bestaaende av en betaadrenerg antagonist och ett tyroideahormon

Info

Publication number
SE461013B
SE461013B SE8800461A SE8800461A SE461013B SE 461013 B SE461013 B SE 461013B SE 8800461 A SE8800461 A SE 8800461A SE 8800461 A SE8800461 A SE 8800461A SE 461013 B SE461013 B SE 461013B
Authority
SE
Sweden
Prior art keywords
pharmaceutical composition
beta
hormone
composition according
lung
Prior art date
Application number
SE8800461A
Other languages
English (en)
Swedish (sv)
Other versions
SE8800461D0 (sv
SE8800461L (sv
Inventor
Christian Wesslau
Ulf Per Gustav Smith
Original Assignee
Christian Wesslau
Ulf Per Gustav Smith
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christian Wesslau, Ulf Per Gustav Smith filed Critical Christian Wesslau
Priority to SE8800461A priority Critical patent/SE461013B/sv
Publication of SE8800461D0 publication Critical patent/SE8800461D0/xx
Priority to AT89902559T priority patent/ATE74767T1/de
Priority to DE8989902559T priority patent/DE68901234D1/de
Priority to EP89902559A priority patent/EP0357725B1/en
Priority to JP1502359A priority patent/JPH03500294A/ja
Priority to PCT/SE1989/000057 priority patent/WO1989007454A1/en
Publication of SE8800461L publication Critical patent/SE8800461L/xx
Priority to NO89894030A priority patent/NO894030L/no
Priority to DK500589A priority patent/DK500589A/da
Priority to FI894809A priority patent/FI894809A0/fi
Publication of SE461013B publication Critical patent/SE461013B/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
SE8800461A 1988-02-11 1988-02-11 Farmaceutisk komposition verksam mot lungobstruktioner bestaaende av en betaadrenerg antagonist och ett tyroideahormon SE461013B (sv)

Priority Applications (9)

Application Number Priority Date Filing Date Title
SE8800461A SE461013B (sv) 1988-02-11 1988-02-11 Farmaceutisk komposition verksam mot lungobstruktioner bestaaende av en betaadrenerg antagonist och ett tyroideahormon
PCT/SE1989/000057 WO1989007454A1 (en) 1988-02-11 1989-02-10 Pharmaceutical composition for treatment of lung obstructions
JP1502359A JPH03500294A (ja) 1988-02-11 1989-02-10 肺閉鎖症の治療用薬剤組成物
DE8989902559T DE68901234D1 (de) 1988-02-11 1989-02-10 Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.
EP89902559A EP0357725B1 (en) 1988-02-11 1989-02-10 Pharmaceutical composition for treatment of lung obstructions
AT89902559T ATE74767T1 (de) 1988-02-11 1989-02-10 Arzneimittelzusammensetzung zur behandlung des lungenverstopfens.
NO89894030A NO894030L (no) 1988-02-11 1989-10-09 Farmasoeytisk blanding for behandling av lungeobstruksjoner
DK500589A DK500589A (da) 1988-02-11 1989-10-10 Farmaceutisk praeparat til behandling af lungeobstruktioner
FI894809A FI894809A0 (fi) 1988-02-11 1989-10-10 Farmakologisk komposition foer behandling av lungobstruens.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8800461A SE461013B (sv) 1988-02-11 1988-02-11 Farmaceutisk komposition verksam mot lungobstruktioner bestaaende av en betaadrenerg antagonist och ett tyroideahormon

Publications (3)

Publication Number Publication Date
SE8800461D0 SE8800461D0 (sv) 1988-02-11
SE8800461L SE8800461L (sv) 1989-08-12
SE461013B true SE461013B (sv) 1989-12-18

Family

ID=20371349

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8800461A SE461013B (sv) 1988-02-11 1988-02-11 Farmaceutisk komposition verksam mot lungobstruktioner bestaaende av en betaadrenerg antagonist och ett tyroideahormon

Country Status (6)

Country Link
EP (1) EP0357725B1 (fi)
JP (1) JPH03500294A (fi)
DK (1) DK500589A (fi)
FI (1) FI894809A0 (fi)
SE (1) SE461013B (fi)
WO (1) WO1989007454A1 (fi)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158978A (en) * 1990-02-05 1992-10-27 British Technology Group (U.S.A.) Thyroid hormone treatment of acute cardiovascular compromise
EP0466909B1 (en) * 1990-02-05 1995-06-28 British Technology Group (Usa) Incorporated Thyroid hormone for cardiac treatment
DE69419721T2 (de) 1993-01-12 2000-04-27 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
ATE390919T1 (de) 2004-11-18 2008-04-15 Uni Pharma Kleon Tsetis Pharmaceutical Lab Sa Trockenpulver mit levothyroxin-natrium mit verabreichung über einen inhalator
LT2558499T (lt) 2010-04-16 2017-07-25 Biogen Ma Inc. Antikūnai prieš vla-4

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH622703A5 (en) * 1976-06-10 1981-04-30 Berema Sa Therapeutic compositions for treating deposits of excess fat and infiltrates causing cellulite
FR2357246A1 (fr) * 1976-07-09 1978-02-03 Martinez Gerard Nouvelles compositions therapeutiques douees d'activite anti-inflammatoire, antalgique et anti-cellulitique
US4086363A (en) * 1977-03-16 1978-04-25 Usv Pharmaceutical Corporation Treatment of asthma
DE3237253A1 (de) * 1981-12-23 1983-10-06 Forschinst Lungen & Tuberkulos Mittel zur beseitigung und verhinderung von belastungsinduzierten und analgetikainduzierten asthma-bronchiale-anfaellen

Also Published As

Publication number Publication date
EP0357725B1 (en) 1992-04-15
DK500589D0 (da) 1989-10-10
EP0357725A1 (en) 1990-03-14
SE8800461D0 (sv) 1988-02-11
FI894809A0 (fi) 1989-10-10
DK500589A (da) 1989-10-10
WO1989007454A1 (en) 1989-08-24
SE8800461L (sv) 1989-08-12
JPH03500294A (ja) 1991-01-24

Similar Documents

Publication Publication Date Title
Maurer et al. Opiate antagonistic properties of an octapeptide somatostatin analog.
US5934273A (en) System for dispensing pharmaceutically active compounds
DE60120936T3 (de) Behandlung von atemerkrankungen
Wildhaber et al. Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants.
Cushley et al. Comparison of three techniques of inhalation on the airway response to terbutaline.
US6250300B1 (en) System for dispensing pharmaceutically active compounds
EA006685B1 (ru) Синергетическая композиция
EP0429430B1 (en) Expectorants comprising n-acetylneuraminic acid
Newman Therapeutic aerosols
NEWMAN How well do in vitro particle size measurements predict drug delivery in vivo?
DE4209989A1 (de) Verbesserte verwendung von b(pfeil abwaerts)2(pfeil abwaerts)-bronchienerweiternden arzneimitteln
RU2006146870A (ru) Минимизация удержания порошка на поверхностях
CA2017383A1 (en) Use of vanilloids for the treatment of respiratory diseases or disorders
JPH06502423A (ja) アミロリドの投薬方法
SE461013B (sv) Farmaceutisk komposition verksam mot lungobstruktioner bestaaende av en betaadrenerg antagonist och ett tyroideahormon
Johnsen et al. Turbuhaler®: a new device for dry powder terbutaline inhalation
SE527200C2 (sv) Inhalatoranordning samt kombinerade doser av formaterol och fluticason
SE527191C2 (sv) Inhalatoranordning samt kombinerade doser av tiotropium och fluticason
Orgel et al. Bitolterol and albuterol metered-dose aerosols: comparison of two long-acting beta2-adrenergic bronchodilators for treatment of asthma
SE527189C2 (sv) Inhalatoranordning samt kombinerade doser för formaterol och ett antikolinergiskt medel
Carpenter et al. Petroleum hydrocarbon toxicity studies: XIV. Animal and human response to vapors of “High Aromatic Solvent”
Newman Therapeutic inhalation agents and devices: effectiveness in asthma and bronchitis
Hartley et al. Long-term comparison of salbutamol powder with salbutamol aerosol in asthmatic out-patients
Darowski et al. Corticosteroids decrease airway hyperresponsiveness in the Basenji-Greyhound dog model of asthma
CN112957350A (zh) 一种鱼腥草雾化吸入用溶液制剂及其制备方法

Legal Events

Date Code Title Description
NUG Patent has lapsed

Ref document number: 8800461-9

Effective date: 19930912

Format of ref document f/p: F